Evidence map›Paper›PMID 31605161›Full record

ReviewDer Nervenarzt2020

[Revised S3 guidelines on schizophrenia : Developmental process and selected recommendations].

Alkomiet Hasan, Peter Falkai, Isabel Lehmann, Birgit Janssen, Thomas Wobrock, Jürgen Zielasek, Wolfgang Gaebel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
    Article
  6. Review
  7. Schizophrenia.Nature reviews. Disease primers · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alkomiet HasanKlinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, Nußbaumstr. 7, 80336, München, Deutschland. Alkomiet.Hasan@med.uni-muenchen.de.
Peter FalkaiKlinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, Nußbaumstr. 7, 80336, München, Deutschland.
Isabel LehmannLVR-Institut für Versorgungsforschung, LVR-Klinik Köln, Köln, Deutschland.
Birgit JanssenLVR-Klinik Langenfeld, Langenfeld, Deutschland.
Thomas WobrockZentrum für seelische Gesundheit, Kreiskliniken Darmstadt-Dieburg, Groß-Umstadt, Deutschland.
Jürgen ZielasekLVR-Institut für Versorgungsforschung, LVR-Klinik Köln, Köln, Deutschland.
Wolfgang GaebelKlinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is one of the most severe mental diseases and leads to significant personal and social impairments for affected persons. The illness is characterized by frequent relapses, results in increased mortality and is associated with the highest socioeconomic costs of all diseases. Moreover, patients with schizophrenia are often stigmatized in everyday life and also in most treatment settings. In 1998 the first German schizophrenia guidelines were published, followed by the first S3 guidelines for schizophrenia in 2006. The revision process started in 2012 coordinated by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) and the revised guidelines were published in 2019. The target group for the revised S3 guidelines includes all persons involved in the care of patients with schizophrenia in all sectors of the German healthcare system, including decision makers and insurance funds. Starting with an introduction of the biological, clinical and epidemiological basis of the disorder, recommendations for the diagnostics of schizophrenia, the detection of comorbidities, the use of antipsychotic medication and other somatic procedures, for psychotherapy, psychosocial interventions, handling of special treatment conditions and rehabilitation are made. Finally, recommendations for an evidence-based and optimal coordination within the healthcare system are made, followed by a discussion of the cost-effectiveness of treatment and presentation of strategies for improved quality management. The most important aspect of the revised S3 guidelines on schizophrenia is the multiprofessional cooperation in all phases of the disorder and an empathic and respectful therapeutic alliance.

Indexed as

Antipsychotic AgentsPsychotic DisordersSchizophreniaHumansPsychotherapyAntipsychotic AgentsCare coordinationCost-effectivenessDifferential diagnosticsRehabilitationTreatment principles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.